March 20 (Reuters) - Eli Lilly LLY.N paid its chief executive David Ricks $36.7 million in 2025, up roughly 25.7% from the previous year, a regulatory filing showed on Friday.

Here are some details:

• Ricks, who has led the company since 2017, received compensation that included salary, stock awards and incentive payments.

• The jump in pay reflects a year in which Lilly continued to expand its position in the drug markets, driven largely by soaring demand for its obesity and diabetes drugs.

• The company's weight-loss drug Zepbound and diabetes treatment Mounjaro have become two of the most closely watched products in the global pharmaceutical industry, helping push Lilly's market value to record highs.

• In 2025, Mounjaro and Zepbound together generated $36.51 billion of the company's total revenue of $65.18 billion.

• Last year, Lilly became the first drugmaker to hit the $1 trillion mark in market value, entering the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.

• Lilly's stock is up 38.1% in 2025 vs. 30.4% in 2024

• CEO Ricks' earnings consist of a $1.7 million salary, $23.3 million in stock awards, $6.5 million in non‑stock incentive pay, $4.45 million from pension value changes and $736,201 in other compensation, according to the filing.

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))